Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo‐Controlled Trial
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Study Objective: To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on β‐cell function. Design: A randomized, double‐blind, placebo‐controlled trial. Setting: Seven hospitals in I taly. Patients: A total of 174 white treatment‐naive adults with type 2 diabetes and a glycated hemoglobin (HbA 1c ) level higher than 7.5%. Intervention: After an open‐label run‐in period of 8 ± 2 months with metformin, patients were randomized to take exenatide (5 μg twice/day for the first 4 weeks, 10 μg twice/day thereafter) or a placebo volume equivalent for 12 months. Measurements and Main Results: Body mass index, H b A 1c , fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin ( FPI ), homeostasis model assessment insulin resistance index, homeostasis model assessment β‐cell function index ( HOMA ‐β), fasting plasma proinsulin ( FPP r), proinsulin‐to‐fasting plasma insulin ratio (Pr: FPI ratio), C ‐peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. H b A 1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA ‐β C‐peptide, and all measures of β‐cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group‐to‐group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. Conclusions: The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, β‐cell function, and inflammatory parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wittamer, V., Franssen, J.-D., Vulcano, M., Mirjolet, J.-F., Le Poul, E., Migeotte, I., Brézillon, S., Tyldesley, R., Blanpain, C., Detheux, M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030382 · Cited by 888
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238352.25222.5e · Cited by 345
Exenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125 · cited 1×
“Exenatide also significantly decreased body weight and improved the inflammatory state as evidenced by a reduction of retinol-binding protein-4 and high-sensitivity C-reactive protein levels.(14) Similar results were observed when exenatide was compared with glimepiride.”
ResultSelf-citationNeuroendocrine and metabolic effects of adipocyte-derived hormones
Jackson, M. B., & Ahima, R. S. (2006) · Clinical Science · doi:10.1042/cs20050243 · Cited by 68
Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67
Cited by
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
NREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Zhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Metadata
- Authors
- Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2013-06-06
- Volume
- 33
- Issue
- 8
- Pages
- 817-826
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2036806748
- Cited by
- 29
- References
- 7
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo‐Controlled Trial. https://app.cochat.ai/papers/10.1002/phar.1301
- The paper
- Derosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2013). Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo‐Controlled Trial. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.1301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.